Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care
Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care
批准号:
10415457
负责人:
Changchun Liu
金额:
$54.73万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2027-04-30
关键词:
2019-nCoVAcetic AcidsAddressAirBioinformaticsBiological AssayCOVID-19 detectionCRISPR/Cas technologyCancer EtiologyCellular PhoneCervical Cancer ScreeningCessation of lifeChemicalsClinicalClinical SensitivityClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplexCytologyDNAData ReportingDetectionDevicesEngineeringEnsureEquipmentEyeFeedbackFundingGenotypeHandHealthHealth PersonnelHuman PapillomavirusHuman papilloma virus infectionImageInfectious Diseases ResearchInterdisciplinary StudyLaboratoriesLesionMalignant neoplasm of cervix uteriMethodsMicrofluidic MicrochipsMicrofluidicsMolecularNucleic AcidsOncologistOpticsPaperPerformancePolymerase Chain ReactionPrintingProceduresProcessPublished CommentRNAReactionReportingReproducibilityResource-limited settingResourcesSamplingSensitivity and SpecificityServicesSpecificitySpeedSwabSystemTechnologyTemperatureTest ResultTestingTimeTrainingUnited States Food and Drug AdministrationVirusVisualWaxesWomanWorld Health OrganizationZambiaanticancer researchbaseburden of illnesschronic infectionclinical applicationcostdesigndetection sensitivitydetectordiagnostic platformemerging pathogenexperienceglobal healthhealth traininghigh riskindustry partnerinnovationinstrumentinternal controllow and middle-income countriesmultiplex detectionnovelpoint of carepoint-of-care diagnosticsportabilityrapid techniquesmartphone Application
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Cervical cancer is among the leading causes of cancer death in women worldwide, especially in low- and middle-
income countries (LMICs). High-risk human papillomaviruses (HPV) are the main causative agents of cervical
cancer and its precursor lesions; therefore, the World Health Organization (WHO) has recommended HPV DNA
testing for cervical cancer screening in LMICs. Although polymerase chain reaction (PCR) methods have been
widely used for HPV DNA detection, they are restricted to centralized clinical laboratories due to the need for
labor-intensive procedures and expensive equipment. Here, we propose to develop a simple, rapid, highly
sensitive, and specific CRISPR-on-paper diagnostic platform to simultaneously detect multiple high-risk HPV
genotypes for cervical cancer screening at the point of care. This innovative diagnostic system is based on our
recently developed all-in-one dual CRISPR-Cas12a (AIOD-CRISPR) assay, which combines the simplicity and
high sensitivity of isothermal nucleic acid amplification with the high specificity of CRISPR detection. To develop
a low-cost, multiplexed molecular detection technology, we will incorporate the AIOD-CRISPR assay into a
paper-based microfluidics platform. To eliminate the need for complex electronic instruments, we will take
advantage of an exothermic reaction to generate chemical heat for the CRISPR-on-paper system by using a
disposable hand warmer, thus enabling instrument-free cervical cancer screening. The detection results can be
read by the naked eye or reported by a programmed smartphone without the need for an expensive optical
detector. We will rigorously evaluate and validate the clinical applications of our CRISPR-on-paper diagnostic
system by testing clinical samples in collaboration with clinicians and healthcare workers in UConn Health and
Zambia. If successful, the proposed project has an important impact on global health by providing a simple,
affordable, and sensitive method for rapid screening of cervical cancer in resource-poor settings. As a platform
technology, the proposed CRISPR-on-paper diagnostic system can be easily adapted to detect other emerging
pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care
-
批准号:10611463
-
项目类别:
-
资助金额:$52.06万
-
财政年份:2022
-
负责人:Changchun Liu
-
依托单位:
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA Detection
-
批准号:10066590
-
项目类别:
-
资助金额:$45.4万
-
财政年份:2020
-
负责人:Changchun Liu
-
依托单位:
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA Detection
-
批准号:10228759
-
项目类别:
-
资助金额:$48.13万
-
财政年份:2020
-
负责人:Changchun Liu
-
依托单位:
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA Detection
-
批准号:10878025
-
项目类别:
-
资助金额:$83.01万
-
财政年份:2020
-
负责人:Changchun Liu
-
依托单位:
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA Detection
-
批准号:10458559
-
项目类别:
-
资助金额:$45.98万
-
财政年份:2020
-
负责人:Changchun Liu
-
依托单位:
A Reaction- Diffusion-Based Approach for Nucleic Acid Quantification
-
批准号:9912154
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2017
-
负责人:Changchun Liu
-
依托单位:
Point of Care Diagnostics of HPV-Associated Cervical Cancer in HIV Epidemic Areas in China
-
批准号:9246115
-
项目类别:
-
资助金额:$16.0万
-
财政年份:2017
-
负责人:Changchun Liu
-
依托单位:
Point of Care Diagnostics of HPV-Associated Cervical Cancer in HIV Epidemic Areas in China
-
批准号:9920096
-
项目类别:
-
资助金额:$15.33万
-
财政年份:2017
-
负责人:Changchun Liu
-
依托单位:
Fully-Integrated, Non-Instrumented Device for Molecular Diagnostics
-
批准号:8653933
-
项目类别:
-
资助金额:$12.84万
-
财政年份:2012
-
负责人:Changchun Liu
-
依托单位:
Fully-Integrated, Non-Instrumented Device for Molecular Diagnostics
-
批准号:8409870
-
项目类别:
-
资助金额:$12.84万
-
财政年份:2012
-
负责人:Changchun Liu
-
依托单位:
Fully-Integrated, Non-Instrumented Device for Molecular Diagnostics
-
批准号:8474692
-
项目类别:
-
资助金额:$12.84万
-
财政年份:2012
-
负责人:Changchun Liu
-
依托单位:
Fully-Integrated, Non-Instrumented Device for Molecular Diagnostics
-
批准号:9055633
-
项目类别:
-
资助金额:$12.84万
-
财政年份:2012
-
负责人:Changchun Liu
-
依托单位:
海外基金